Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Dihydroergotamine Mesylate Patent Expiration

Dihydroergotamine Mesylate is used for acute treatment of migraine with or without aura. It was first introduced by Bausch Health Us Llc in its drug D.H.E. 45 on Approved Prior to Jan 1, 1982. Other drugs containing Dihydroergotamine Mesylate are Migranal, Trudhesa. 11 different companies have introduced drugs containing Dihydroergotamine Mesylate.


Dihydroergotamine Mesylate Patents

Given below is the list of patents protecting Dihydroergotamine Mesylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Trudhesa US10507295 Nasal drug delivery device Dec 25, 2032 Impel Pharms
Trudhesa US10940278 Nozzles for nasal drug delivery Jan 23, 2033 Impel Pharms
Trudhesa US11185497 Intranasal delivery of dihydroergotamine by precision olfactory device Jan 04, 2039 Impel Pharms
Trudhesa US11266799 In-line nasal delivery device Nov 05, 2036 Impel Pharms
Trudhesa US9550036 Nasal drug delivery device Sep 05, 2032 Impel Pharms
Trudhesa US9919117 Nozzles for nasal drug delivery Mar 17, 2033 Impel Pharms



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dihydroergotamine Mesylate's patents.

Given below is the list recent legal activities going on the following patents of Dihydroergotamine Mesylate.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Yr, Small Entity 11 Jul, 2024 US9550036
Payment of Maintenance Fee, 4th Yr, Small Entity 11 Jul, 2024 US10940278
Change in Power of Attorney (May Include Associate POA)
Critical
 02 Apr, 2024 US11185497
Email Notification
Critical
 02 Apr, 2024 US11185497
Change in Power of Attorney (May Include Associate POA)
Critical
 01 Apr, 2024 US9550036
Email Notification
Critical
 01 Apr, 2024 US9550036
Email Notification
Critical
 29 Mar, 2024 US10940278
Change in Power of Attorney (May Include Associate POA)
Critical
 29 Mar, 2024 US10940278
Email Notification
Critical
 28 Mar, 2024 US11266799
Change in Power of Attorney (May Include Associate POA)
Critical
 28 Mar, 2024 US11266799



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Dihydroergotamine Mesylate Generics

Several generic applications have been filed for Dihydroergotamine Mesylate. The first generic version for Dihydroergotamine Mesylate was by Padagis Us Llc and was approved on Apr 28, 2003. And the latest generic version is by Gland Pharma Ltd and was approved on Aug 18, 2023.

Given below is the list of companies who have filed for Dihydroergotamine Mesylate generic.


1. AMNEAL

Amneal Pharmaceuticals Llc has filed for 1 generic for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Amneal.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.5MG/SPRAY spray, metered Discontinued NASAL N/A Jan 4, 2022


2. CIPLA

Cipla Ltd has filed for 1 generic for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Cipla.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.5MG/SPRAY spray, metered Prescription NASAL AB May 20, 2020


3. GLAND PHARMA LTD

Gland Pharma Ltd has filed for 1 generic for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1MG/ML injectable Prescription INJECTION AP Aug 18, 2023


4. HIKMA

Hikma Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Hikma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1MG/ML injectable Prescription INJECTION AP Jun 9, 2003
0.5MG/SPRAY spray, metered Prescription NASAL AB Feb 28, 2020


5. HIKMA PHARMS

Hikma Pharmaceuticals has filed for 1 generic for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Hikma Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1MG/ML

(reference standard)

injectable Prescription INJECTION AP Sep 15, 2017


6. PADAGIS US

Padagis Us Llc has filed for 1 generic for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Padagis Us.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1MG/ML injectable Prescription INJECTION AP Apr 28, 2003


7. PROVEPHARM SAS

Provepharm Sas has filed for 1 generic for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Provepharm Sas.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1MG/ML injectable Prescription INJECTION AP Jan 7, 2020


8. RUBICON

Rubicon Research Private Ltd has filed for 1 generic for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Rubicon.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.5MG/SPRAY spray, metered Prescription NASAL AB Jun 22, 2023


9. SAGENT PHARMS INC

Sagent Pharmaceuticals Inc has filed for 1 generic for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Sagent Pharms Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1MG/ML injectable Prescription INJECTION AP Jul 11, 2018